Advanced Filters
noise

Bryn Mawr, Pennsylvania Clinical Trials

A listing of Bryn Mawr, Pennsylvania clinical trials actively recruiting patient volunteers.

Found 1,068 clinical trials

SBRT With Atezo/Bev for HCC

A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)

18 - 99 years of age All Phase 1

Effects of the Contraceptive Implant in Women With Sickle Cell Disease

The objective of this study is to measure the acceptability and impact of the progestin implant on frequency of vaso-occlusive crises, quality of life, and hematologic parameters in women with SCD.

18 - 45 years of age Female Phase 4
C Chelsea Botang

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.

18 - 80 years of age All Phase 3
C Cassandra J Demastus

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism \[Empagliflozin (Empa)\], with and without additional supplements that increase perfusion and fatty acid oxidation \[Potassium Nitrate (KNO3)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure …

18 years of age All Phase 2

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)

18 years of age All Phase 1
M Melissa Varghese, BA

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

This study will determine the safety and efficacy of moving to a second-generation manufacturing process using the CliniMACS Prodigy platform to manufacture huCART19 cells for patients with B cell Acute Lymphoblastic Leukemia (B-ALL).

- 29 years of age All Phase 1/2
J Jessica Sharpe

ETHAN - ET for Male BC

This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: Tamoxifen Anastrozole Degarelix Abemaciclib

18 years of age Male Phase 2
C Corey Langer, MD

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).

18 years of age All Phase 1

Role of the Immune Environment in Response to Therapy in Breast Cancer

This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.

18 years of age Female Phase N/A
M Morgan L Gabbert, MA

SHAPE of Portal Hypertension in Children

Early diagnosis of portal hypertension is difficult as symptoms rarely manifest until the later stages of liver disease. Both cirrhotic and non-cirrhotic portal hypertension can result in life-threatening complications, the most frequent of which is bleeding from esophageal varices. In children, variceal bleeds are associated with mortality rates of 1-3 …

6 - 21 years of age All Phase 2

Simplify language using AI